After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The stock has broken free of tiresome resistance in a big way.
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.
The company sans CEO Scangos needs to do some type of deal in the coming months.
Pfizer shares are up 13% year to date, and the company reports earnings on Aug. 2. Here's what to expect.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.